Editas Medicine, Inc.

The momentum for this stock is not very good. Editas Medicine, Inc. is not a good value stock. Editas Medicine, Inc. is not a good growth stock. Editas Medicine, Inc. is not very popular among insiders. Editas Medicine, Inc. is a mediocre stock to choose.
Log in to see more information.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology....
EDIT Fundamental Data by TradingView

News

Koss Olinger Consulting LLC Makes New Investment in Editas Medicine, Inc. (NASDAQ:EDIT)
Koss Olinger Consulting LLC Makes New Investment in Editas Medicine, Inc. (NASDAQ:EDIT)

Ticker Report Koss Olinger Consulting LLC acquired a new stake in shares of Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) in the second quarter, according to its most recent disclosure with the Securities...\n more…

Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript)

SeekingAlpha Editas Medicine, Inc. (EDIT) Presents at Wells Fargo 2024 Healthcare Conference (Transcript...\n more…

Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)

SeekingAlpha Editas Medicine, Inc. (EDIT) Presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript...\n more…

Q3 2024 Earnings Forecast for Editas Medicine, Inc. Issued By Zacks Research (NASDAQ:EDIT)
Q3 2024 Earnings Forecast for Editas Medicine, Inc. Issued By Zacks Research (NASDAQ:EDIT)

Zolmax Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) - Equities research analysts at Zacks Research decreased their Q3 2024 earnings per share (EPS) estimates for Editas Medicine in a note issued to...\n more…

Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine to Participate in Upcoming Investor Conferences

Globe Newswire CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced that management will participate in the following...\n more…

Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Assenagon Asset Management S.A.
Editas Medicine, Inc. (NASDAQ:EDIT) Shares Sold by Assenagon Asset Management S.A.

Ticker Report Assenagon Asset Management S.A. lessened its position in Editas Medicine, Inc. (NASDAQ:EDIT - Free Report) by 59.1% during the second quarter, according to the company in its most recent 13F filing...\n more…